Compare
Abbott Laboratories vs Enovis (ABT vs ENOV)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and Enovis (ENOV) -13.8%; so far this year the figures are -12.3% and +1.9%.
Abbott Laboratories is the larger company by market value, about 121.3 times the size of Enovis.
Revenue grew +10.0% at ABT and +3.3% at ENOV over the last year.
ABT yields 2.29%. ENOV pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | ENOV | |
|---|---|---|
| Price | $109.93 | $27.16 |
| 1-day | -3.23% | -5.10% |
| YTD | -12.26% | +1.95% |
| 1 year | -11.73% | -13.75% |
| 3 years | +15.70% | -39.68% |
| Market cap | $190.4B | $1.6B |
| P/E | 40.9 | — |
| P/S | 3.95 | 0.68 |
| P/B | 3.73 | 1.05 |
| Revenue growth | +10.00% | +3.30% |
| EPS growth | -66.20% | — |
| Gross margin % | 56.9 | 61.3 |
| Net margin % | 9.7 | -22.9 |
| ROE % | 9.2 | -35.3 |
| Debt / equity | 0.61 | 0.84 |
| FCF yield % | 3.5 | 4.4 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 1.04 |
| RSI (14) | 58.5 | 69.3 |
| Technical rating |